Honeybear Biosciences Bringing Total Funds Raised to $34 Million to Accelerate Lead Radiopharmaceutical Candidates into Clinical Trial
Honeybear Biosciences Inc. announces the completion of a US $20 million Series A financing round, bringing the total capital raised to US $34 million, making it one of Taiwan’s most notable fundraising examples in the next-generation nuclear medicine and precision oncology sectors in recent years. The newly raised capital will primarily support the development of Honeybear’s Antibody-Radionuclide Conjugate (ARC) therapeutics into international clinical trials, further strengthening the company’s competitive position in the global next-generation precision cancer therapeutics market.
Within the rapidly advancing field of precision and nuclear medicine, ARC’s are widely regarded as one of the most promising emerging modalities of radiopharmaceuticals, following the dramatic success of Antibody-Drug Conjugates (ADCs). By leveraging the highly targeted nature of antibodies to precisely deliver radiation to cancer cells, ARC technology enables both tumor imaging and therapeutic intervention, creating an integrated “theranostics” approach to precision oncology. In recent years, major global pharmaceutical and nuclear medicine companies have increasingly invested in this field, driving rapid growth of the global radiopharmaceuticals market.
Honeybear Biosciences is the first company in Taiwan to establish a comprehensive ARC development platform and pipeline, and continues to strengthen its in-house R&D capabilities. The company is currently advancing multiple ARC and ADC candidates, with preclinical studies demonstrating favorable tumor accumulation, excellent stability, and promising safety profiles. These candidates are designed to maximize therapeutic efficacy while minimizing damage to healthy tissues. By focusing on highly expressed tumor targets and optimized radionuclide and chemical payload pairing strategies, Honeybear Bio aims to improve tumor eradication and patient tolerability through innovative drug design.
Honeybear’s lead candidate, HB001, has entered late-stage preclinical development, with an Investigational New Drug (IND) application targeted by the end of 2026 to initiate first-in-human clinical studies. HB002, Honeybear’s second radiopharmaceutical candidate, is expected to reach IND stage in 2027.
CoNectar® Platform Strengthens Next-Generation ADC and ARC Innovation
Beyond its ARC pipeline, Honeybear’s proprietary CoNectar® platform is attracting industry attention. Through highly site-specific glycan conjugation and dual payload engineering, CoNectar® enables precise control over conjugation sites and Drug-to-Antibody Ratios (DAR), effectively overcoming the heterogeneity issues commonly associated with conventional conjugation technologies. This technology is designed to enhance stability, consistency, efficacy and safety.
Compared with traditional ADC conjugation technologies, the CoNectar® platform not only improves product quality but also offers significant advantages in process scalability and commercial manufacturing. The platform currently achieves process yields exceeding 90%, helping reduce manufacturing costs and shorten development timelines. Its highly modular design also enables flexible applications across next-generation ADCs, ARCs, and other novel biologics, forming a strong foundation for future partnerships and licensing opportunities.
Expanding Global Partnerships to Accelerate Precision Oncology
In recent years, Honeybear Biosciences has actively expanded international collaborations, engaging with global nuclear medicine and biotechnology partners, including Memorial Sloan Kettering Cancer Center, PET Pharm Biotech Co., Ltd, the University of California, San Francisco (UCSF), Singapore’s ASTAR*, the Development Center for Biotechnology and multiple CDMO partners to strengthen radionuclide supply, clinical resource integration, manufacturing and global market access strategies.
As global demand for precision oncology continues to rise, the company believes that ARC products with integrated diagnostic and therapeutic properties are poised to drive the next wave of innovation in cancer treatment.
The strong success of this Series A financing round not only reflects investors’ confidence in Honeybear’s innovative ARC and ADC development strategy but also highlights Taiwan’s growing international visibility in next-generation radiopharmaceutical development. Looking ahead, Honeybear Biosciences will continue advancing its CoNectar® platform and next-generation ADC/ARC pipelines while accelerating global licensing and strategic partnership opportunities, with the goal of becoming a globally prominent biotechnology innovator.
Please visit the related news link for more details：
Honeybear Biosciences Inc. announces the completion of a US $20 million Series A financing round, bringing the total capital raised to US $34 million, making it one of Taiwan’s most notable fundraising examples in the next-generation nuclear medicine and precision oncology sectors in recent years. The newly raised capital will primarily support the development of Honeybear’s Antibody-Radionuclide Conjugate (ARC) therapeutics into international clinical trials, further strengthening the company’s competitive position in the global next-generation precision cancer therapeutics market.
Advancing Taiwan’s First ARC Platform Toward Global Clinical Development
Within the rapidly advancing field of precision and nuclear medicine, ARC’s are widely regarded as one of the most promising emerging modalities of radiopharmaceuticals, following the dramatic success of Antibody-Drug Conjugates (ADCs). By leveraging the highly targeted nature of antibodies to precisely deliver radiation to cancer cells, ARC technology enables both tumor imaging and therapeutic intervention, creating an integrated “theranostics” approach to precision oncology. In recent years, major global pharmaceutical and nuclear medicine companies have increasingly invested in this field, driving rapid growth of the global radiopharmaceuticals market.
Honeybear Biosciences is the first company in Taiwan to establish a comprehensive ARC development platform and pipeline, and continues to strengthen its in-house R&D capabilities. The company is currently advancing multiple ARC and ADC candidates, with preclinical studies demonstrating favorable tumor accumulation, excellent stability, and promising safety profiles. These candidates are designed to maximize therapeutic efficacy while minimizing damage to healthy tissues. By focusing on highly expressed tumor targets and optimized radionuclide and chemical payload pairing strategies, Honeybear Bio aims to improve tumor eradication and patient tolerability through innovative drug design.
Honeybear’s lead candidate, HB001, has entered late-stage preclinical development, with an Investigational New Drug (IND) application targeted by the end of 2026 to initiate first-in-human clinical studies. HB002, Honeybear’s second radiopharmaceutical candidate, is expected to reach IND stage in 2027.
CoNectar® Platform Strengthens Next-Generation ADC and ARC Innovation
Beyond its ARC pipeline, Honeybear’s proprietary CoNectar® platform is attracting industry attention. Through highly site-specific glycan conjugation and dual payload engineering, CoNectar® enables precise control over conjugation sites and Drug-to-Antibody Ratios (DAR), effectively overcoming the heterogeneity issues commonly associated with conventional conjugation technologies. This technology is designed to enhance stability, consistency, efficacy and safety.
Compared with traditional ADC conjugation technologies, the CoNectar® platform not only improves product quality but also offers significant advantages in process scalability and commercial manufacturing. The platform currently achieves process yields exceeding 90%, helping reduce manufacturing costs and shorten development timelines. Its highly modular design also enables flexible applications across next-generation ADCs, ARCs, and other novel biologics, forming a strong foundation for future partnerships and licensing opportunities.
Expanding Global Partnerships to Accelerate Precision Oncology
In recent years, Honeybear Biosciences has actively expanded international collaborations, engaging with global nuclear medicine and biotechnology partners, including Memorial Sloan Kettering Cancer Center, PET Pharm Biotech Co., Ltd, the University of California, San Francisco (UCSF), Singapore’s ASTAR*, the Development Center for Biotechnology and multiple CDMO partners to strengthen radionuclide supply, clinical resource integration, manufacturing and global market access strategies.
As global demand for precision oncology continues to rise, the company believes that ARC products with integrated diagnostic and therapeutic properties are poised to drive the next wave of innovation in cancer treatment.
The strong success of this Series A financing round not only reflects investors’ confidence in Honeybear’s innovative ARC and ADC development strategy but also highlights Taiwan’s growing international visibility in next-generation radiopharmaceutical development. Looking ahead, Honeybear Biosciences will continue advancing its CoNectar® platform and next-generation ADC/ARC pipelines while accelerating global licensing and strategic partnership opportunities, with the goal of becoming a globally prominent biotechnology innovator.
Please visit the related news link for more details：
- GENEONLINE https://www.geneonline.com/honeybear-biosciences-arc-utm_sourcegoogleutm_mediumgoogle_20260701utm_campaignhoneybear/
- ENDPOINTS NEWS https://endpoints.news/sp/honeybear-biosciences-bringing-total-funds-raised-to-34-million-to-accelerate-lead-radiopharmaceutical-candidates-into-clinical-trial/
